Simtra BioPharma Solutions Invests $250 Million to Expand Sterile Fill/Finish Manufacturing Site, Indiana

Specifications:

Name:

Simtra BioPharma Solutions Invests $250 Million to Expand Sterile Fill/Finish Manufacturing Site, Indiana

Location:

Bloomington, Indiana

Company:

Simtra BioPharma Solutions

Estimated Cost:

$250 Million

Source:

https://biopharmasolutions.baxter.com

Introduction:

Simtra BioPharma Solutions (Simtra), a premier injectable contract development and manufacturing organization (CDMO) announced a $250+ million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana.

Features:

A new, state of the art 150,000 square foot building will be constructed to house two high-speed automated isolator syringe fill lines and a new high speed isolator vial line equipped with three 30 square meter lyophilizers. Each process suite in the new building will be fitted with dedicated formulation/compounding rooms.

The expansion will also include the addition of a dedicated clinical line equipped to support our growing development/clinical business. This line will utilize existing facility infrastructure.

The clinical line is expected to be ready to onboard new projects by summer 2025. It will provide the Bloomington campus the ability to better accommodate projects that are in early phases of development (Phase I or II) and keep these projects onsite as they scale up for commercialization.

Construction of the new building is planned to begin in June 2024 and anticipated to take two years to complete, allowing for GMP readiness in late 2026. In aggregate, the expansion is expected to create hundreds of new jobs in Bloomington.

This latest expansion follows a $100+ million investment in Simtra's Halle/Westfalen, Germany site in 2021 for the construction of a new building housing a high-speed syringe line and a vial line equipped with four lyophilizers. GMP readiness is anticipated by the end of 2024.